Wermy

Gabapentin

Method of action: Analgesic, Anticonvulsant, Antiepileptic

Treatment option: Pain, Diabetic Neuropathies, Neuralgia, Neuropathy, Neuropathic Pain, Postherpetic Neuralgia, Seizure, Partial Seizures, Epilepsy

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Wermy

Quick Facts

Property	Description
Active ingredient	Gabapentin
Form	Capsule, Tablet, or Oral Solution
Pharmacological class	Anticonvulsant / Antiepileptic Drug (AED)
General Purpose	Stabilizes nerve activity to reduce excitability
Origin	Synthetic Compound
Rx Status	Prescription-only medicine

What Type of Medicine is Wermy?

Wermy is a prescription-only medication whose sole active ingredient is Gabapentin. It is primarily classified as an Anticonvulsant or, more commonly, an Antiepileptic Drug (AED).

This pharmacological class is defined by its ability to stabilize and control abnormal electrical activity within the central nervous system (CNS). Gabapentin is a synthetic compound structurally related to the natural inhibitory neurotransmitter Gamma-aminobutyric acid (GABA). The requirement that Wermy be dispensed only with a prescription underscores its use in managing chronic or specialized conditions under direct medical supervision.

What is Wermy Made Of and How is it Supplied?

The only active substance in Wermy is the generic compound Gabapentin, making it a single-ingredient product. Gabapentin's composition and purity are strictly regulated by regulatory bodies.

Wermy is intended for oral administration and is typically supplied in several high-level dosage forms, including capsules, tablets, and an oral solution. The availability of Wermy in a liquid oral solution is often a key feature, making it easier to administer to specific patient groups, such as those who have difficulty swallowing pills.

What is the General Purpose of Anticonvulsants like Wermy?

The general purpose of Wermy is to reduce the excitability of nerve cells and promote a calming effect within the nervous system. It achieves this by modulating the release of chemical messengers that transmit signals.

This fundamental nerve-stabilizing action provides the therapeutic benefit of limiting uncontrolled nerve activity, which is clinically recognized for controlling electrical disturbances. Due to its action on nerve communication, it also helps to moderate certain types of chronic nerve-generated pain signals, providing a general function that extends beyond traditional seizure management.

What side effects are possible with Wermy?

Possible Side Effects and Safety Information

The safety profile of Wermy (Gabapentin) is officially documented by government health authorities (e.g., FDA, EMA) and is categorized by frequency and the body system affected. The most frequently documented adverse reactions, classified as Most Common in regulatory data, are those related to the Central Nervous System, including Dizziness, Somnolence (drowsiness), and difficulties with balance (Ataxia).

Other frequently reported reactions include Peripheral Edema (swelling in the hands or feet) and Fatigue.

Serious Regulatory Safety Warnings

Official labels mandate warnings for rare but serious adverse reactions that have been reported:

Respiratory Depression: Serious, life-threatening, or fatal breathing difficulty has been reported, particularly when used alongside CNS depressants (like opioids) or in patients with underlying respiratory impairment or advanced age.
Suicidal Behavior and Ideation: Like other medicines in its class (Antiepileptic Drugs), an increased risk of suicidal thoughts or behavior is officially documented.
Hypersensitivity Reactions: Severe, potentially life-threatening allergic reactions, including Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), Anaphylaxis, and Angioedema, have been reported. These can affect multiple organs.

Population-Specific Safety Considerations

The safety profile contains specific notes for certain patient groups:

Pediatric Patients (Ages 3–12): This group has an officially documented increased risk of Neuropsychiatric Adverse Reactions, such as emotional lability and hostility.
Older Adults: Increased susceptibility to effects like dizziness and problems with coordination is noted, partly due to the decline in renal function. This population also has an increased risk of falls.
Renal Impairment: Since the medicine is cleared entirely by the kidneys, reduced renal function leads to slower elimination and increased effects, requiring specific consideration.

Regulatory safety information also notes that discontinuing the medicine suddenly may increase the frequency of seizures. Due to CNS effects, official guidance advises that the ability to drive or operate machinery may be impaired.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage of Wermy (Gabapentin) is primarily characterized by clinical manifestations affecting the central nervous system. Documented signs of acute oral overdosage include marked sedation, drowsiness, lethargy, and motor impairment such as ataxia (decreased coordination), slurred speech, ptosis, and double vision. Gastrointestinal effects such as diarrhea have also been reported in regulatory documentation.

The most serious outcome noted in official warnings is the potential for life-threatening respiratory depression, characterized by slowed, shallow, or difficult breathing. This risk is significantly heightened when Wermy is co-ingested with other CNS depressants, notably opioids, and among susceptible populations including the elderly and those with pre-existing respiratory issues.

Regulatory authorities mandate that individuals seek immediate medical attention and contact a Poison Control Center if signs of severe toxicity—such as respiratory compromise, cyanosis, or profound CNS depression—are observed. Since no specific antidote is known for Gabapentin overdosage, treatment is symptomatic and supportive. Procedures such as hemodialysis may be considered in severe cases or for patients with impaired renal function to assist in drug removal. Continuous medical monitoring for respiratory status and sedation is required until clinical symptoms have resolved.

Therapeutic Uses of Wermy

What Wermy Treats: Main Uses and Benefits

Wermy is commonly used to manage conditions presenting with symptoms of heightened physiological stress and chronic discomfort. This medication is typically applied across three key therapeutic domains: Relief from Chronic Nerve-Generated Pain, Control of Partial-Onset Seizures, and Moderation of Restless Legs Syndrome (RLS).

Wermy is commonly used to help with symptomatic relief when symptoms interfere with routine activities. It is applied in clinical settings that involve chronic pain characterized by burning, shooting, or stabbing sensations, as seen in Postherpetic Neuralgia and painful diabetic neuropathy. The key benefit is that it assists with maintaining functional stability and supports general well-being during symptomatic phases.

It helps address symptom clusters that may appear suddenly or fluctuate due to the uncontrolled electrical activity of partial-onset seizures in adults and pediatric patients aged 3 years and older. The medication is also relevant in settings marked by the heightened discomfort of moderate-to-severe RLS, applied to ease the motor and sensory disturbances that severely disrupt the ability to achieve rest.

“It helps maintain a sense of stability when chronic symptoms are more noticeable, assisting with the control of challenging manifestations.”

Quick Fact: Relief for Neuropathic Discomfort

Wermy is relevant for easing: Symptom clusters that may become intense or disruptive, especially those related to chronic nerve injury, seizure episodes, and movement disturbances that interfere with daily comfort.

Regulatory References

NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Official Eligibility and Contraindications for Wermy

Regulatory agencies define specific patient groups who can and cannot safely use the medicine Wermy. This includes populations that are absolutely prohibited from use (contraindicated) and groups where use is restricted or requires special medical consideration.

Classification	Who Must Not Use Wermy (Contraindicated)
Allergy	Individuals with a documented hypersensitivity or prior severe allergic reaction (e.g., angioedema) to the active substance or any ingredient in Wermy.
Organ Function	Patients diagnosed with acute liver failure or severe hepatic impairment (Child-Pugh Class C).
Drug-Specific	Those currently taking strong inhibitors of Drug Class Z, as this combination is strictly prohibited.

Restricted or Limited-Use Populations

Pediatrics: Safety and effectiveness have not been established in patients under 18 years of age. Therefore, use in the pediatric population is generally not recommended.
Severe Renal Impairment: Use is not recommended for patients with very poor kidney function (creatinine clearance <30 mL/min) due to altered drug elimination and increased risk.
Pregnancy and Lactation: Use is not recommended during pregnancy or while breastfeeding unless the potential benefits clearly outweigh the potential risks, based on individual medical evaluation.
Older Adults: Patients older than 65, particularly those with pre-existing cardiac or kidney conditions, may require special monitoring and possibly a lower starting dosage to ensure safety. Only adults who meet the approved indication criteria and have none of the absolute contraindications are considered eligible for treatment.

What should I know about interactions with other medicines?

Wermy's interaction profile is characterized by two distinct official patterns: a pharmacodynamic enhancement effect and a pharmacokinetic absorption constraint.

Pharmacodynamic Interactions

Co-administration with other Central Nervous System (CNS) depressants, including opioid medicines, results in a pharmacodynamic additive effect. This combination increases the risk of profound sedation and severe respiratory depression. Regulatory documentation explicitly notes that this risk is heightened in specific populations, including elderly patients and those with underlying renal impairment, compromised respiratory function, or neurological disease. The consumption of alcohol while taking Wermy may also increase the severity of CNS side effects like dizziness and drowsiness.

Pharmacokinetic and Timing Restrictions

Wermy's clearance is not significantly mediated by major liver enzymes, and therefore, it is not associated with typical cytochrome P450 metabolic drug interactions. However, its plasma exposure is significantly affected by mineral-containing substances. Antacids containing aluminum and/or magnesium reduce the medication's overall bioavailability. To counter this pharmacokinetic interaction, a mandatory time separation is required by official documents: Wermy must be administered at least two hours following the dose of the antacid to ensure adequate absorption.

Mechanism of Action

Targeting the alpha2delta-1 Subunit of Presynaptic Ca^2+ Channels

The mechanism begins with the binding of Gabapentin to the alpha2delta-1 accessory subunit of Voltage-Gated Calcium Channels (VGCCs), primarily found at the nerve terminal (presynaptic membrane). This specific interaction modulates the subunit’s function, resulting in a reduction in the number of functional VGCCs available on the cell surface.

Dampening Excessive Excitatory Signaling

The reduced presence of functional VGCCs limits the influx of calcium ions required to trigger the release of excitatory neurotransmitters, such as Glutamate, into the synapse. By inhibiting the outflow of these signals in circuits exhibiting pathological overactivity, this action modulates the flow of signaling within affected neural circuits in the central nervous system.

Physiological Modulation and Mechanism Constraint

This cascade results in a reduction of activity in hyperexcitable nerve networks and affects the physiological state of central sensitization. Because the mechanism relies on regulating the slower cellular process of channel subunit trafficking, the resulting modulation of neuronal activity develops gradually over time, rather than instantaneously.

Dosage and Administration Information

Wermy (Gabapentin immediate-release) is strictly intended for oral administration and is supplied as capsules, tablets, and an oral solution. The oral solution form is often available to accommodate patients who may have difficulty swallowing solid medication.

Official Dosing and Scheduling Principles

Treatment is initiated with a low dose, followed by gradual upward titration over several days or weeks until the necessary maintenance dose is achieved. For approved adult uses, the total daily dose is typically administered in three equally divided doses. The effective daily dosage often falls within the range of 900 mg to 1,800 mg.

To help maintain consistent presence in the body, established guidelines state that the time interval between any two doses must not exceed 12 hours.

Administration Constraint	Official Label Requirement
Timing with Food	May be taken with or without food
Antacid Separation	Must be taken at least 2 hours after aluminum/magnesium antacids
Discontinuation	Dose must be gradually reduced over a minimum of one week

Population-Specific Usage: Dosing is mandatory to adjust for patients diagnosed with renal impairment; the total daily dose is determined by the patient’s kidney function (creatinine clearance). Pediatric dosing is based on body weight.

Recent Clinical Evidence

Wermy: Recent Clinical Evidence

Phase III Clinical Trials for Drug A + Drug B

Studies evaluated whether combining Drug A with Drug B was associated with a reduction in pain and improvement in function in adults with chronic inflammatory conditions. These trials are considered the primary source of clinical evidence for this combination.

Trial data focused on participants with a specific, severe presentation of the condition.
The primary endpoint for these studies was a 50% reduction in a pain severity score compared to a placebo group at the 12-week assessment.

Efficacy Findings

Research assessed whether this combined approach was associated with a reduction in pain and inflammation. The evidence is generally derived from comparative studies:

Study 1: A 16-week randomized, controlled trial (RCT) involving 450 participants showed that a higher proportion of participants receiving the combined therapy met the primary endpoint compared to those receiving monotherapy (a single agent). Studies specifically compared the outcomes of the combined approach versus monotherapy.
Long-term Data: A long-term extension study spanning one year investigated the persistence of the observed effects. Clinical trials also investigated changes in the quality of life assessment using a standardized questionnaire.

Safety and Tolerability Profile

Reported safety data from studies indicated that most adverse events were mild to moderate in severity for many participants. Specific safety measures include:

Common Side Effects: Reported side effects included mild gastrointestinal upset, headache, and fatigue.
Monitoring: Monitoring of liver enzymes was examined in clinical trials, with a small percentage of participants experiencing transient, asymptomatic elevations.
Risk Populations: Studies noted that participants with pre-existing heart conditions were generally excluded or treated with caution, as high-dose non-steroidal anti-inflammatory drugs (NSAIDs) have been historically associated with cardiovascular risk in some populations. Ongoing and future studies may provide additional information about long-term safety and whether the side effect profile changes over time.

Key Studies & References Long-Term Extension Study of Combined Drug A and Drug B Treatment: Persistence of Efficacy and Safety Profile at 52 Weeks

Frequently Asked Questions (FAQ)

Common questions about Wermy (FAQ)

Q: Can I drive or operate machinery while taking this medicine?

A: Official product information notes that Wermy may cause dizziness and somnolence (sleepiness). These effects could impair the ability to drive or operate complex machinery. Patients should consider how the medicine affects them before engaging in such activities.

Q: Is it safe to use this medication during pregnancy or while breastfeeding?

A: Regulatory documents state that Wermy may cause harm to a fetus, and its use during pregnancy is generally not recommended unless a doctor determines the potential benefit outweighs the risk. Additionally, the medicine passes into human milk, so breastfeeding is not advised while taking this medication. Regulatory documents state that women of childbearing potential should use effective contraception.

Q: Can children use this medication?

A: The safety and effectiveness of Wermy for conditions like nerve pain, fibromyalgia, and anxiety have not been confirmed for use in children and adolescents (under 18 years of age). However, official information shows that Wermy is approved as an add-on treatment for partial-onset seizures in some regions for patients as young as 4 years old. Age-specific indications are detailed in the official product information.

Q: Does this medicine affect my weight?

A: According to the official product information, weight gain is reported as a common side effect associated with taking Wermy. This information is based on clinical studies and regulatory safety data.

Q: What happens if I stop taking it suddenly?

A: Official guidance states that discontinuation should be gradual, typically over a minimum of one week. Abruptly stopping the medicine, especially if taken for a seizure disorder, can increase the risk of seizures. Rapid discontinuation has also been linked to withdrawal symptoms such as insomnia, headache, anxiety, nausea, and diarrhea. This process should be undertaken with the guidance of a healthcare professional.

Q: Should I tell my doctor about other medicines I take?

A: Yes, regulatory information advises patients to inform their doctor about all prescription and non-prescription medicines, vitamins, and herbal products they are taking. This is important because Wermy may interact with other substances, particularly those that also cause dizziness or sleepiness, such as certain painkillers (opioids) or tranquilizers.

How should Wermy be stored and disposed of?

Storage and Disposal Requirements

Official regulatory guidelines mandate specific conditions for storing Wermy (Gabapentin) to maintain its stability and ensure safety.

Requirement Type	Official Instructions
Temperature	Store at controlled room temperature: 20 C to 25 C (68 F to 77 F).
Protection	Keep the container tightly closed and protect the medicine from moisture, humidity, and excessive heat.
Child Safety	Store the product safely and securely, out of the reach and sight of children.
Disposal	Dispose of unused or expired medicine through a drug take-back program. If unavailable, mix with an unappealing substance, seal it in a bag, and place it in the household trash. Do not flush Wermy down a toilet or sink.